Korro Bio (KRRO) Insider Francois Sells $55K of Stock

Formela Jean Francois sold 3,962 shares of Korro Bio, Inc. (KRRO) on the NasdaqCM on June 22, 2026. The transaction was valued at $55,269.90 and was carried out under a prearranged Rule 10b5-1 trading plan. This specific sale was part of a broader series of transactions by the same individual during the same week.

Insider Buying and Selling at Korro Bio, Inc.

This sale is one of several recent trades by company insiders. Formela Jean Francois followed up the June 22 transaction with a larger sale of 48,438 shares on June 24, 2026, at a price of $14.61, worth about $707,490. Earlier in the month, on June 16, 2026, Chief Operating Officer Todd Chappell sold 3,168 shares for $34,309.44. On that same day, Chief Scientific Officer Loic Vincent sold 3,418 shares for $37,016.94, and Oliver Dolan, the Senior Vice President of Finance, sold 3,383 shares for $36,637.89. All three of the June 16 trades occurred at a price of $10.83 per share.

Korro Bio Stock Trends

On Thursday, Korro Bio shares were priced at $13.77. The stock has stayed above its recent technical benchmarks, including the 50-day moving average of $12.40 and the 200-day moving average of $11.58. While the current price is well above the 52-week low of $5.20, it remains far from the 52-week high of $55.89. The company has a beta of 2.25, which means the stock tends to be much more volatile than the broader market.

Recent Earnings Data

Korro Bio reported revenue of $2.38 million in its most recent reporting period. The company is currently in a growth and development phase, reporting an earnings per share (EPS) loss of $9.88 and a return on equity of -0.97. Because it is not currently profitable, the company does not have a meaningful P/E ratio. Investors are looking toward the next scheduled earnings date on November 12, 2026.

Analysts Set New Price Targets

Several analysts have kept a close eye on the biotechnology firm. On October 6, 2026, HC Wainwright & Co. reiterated a Buy rating on the stock with a $15.00 price target. This was a repeat of the same firm's rating and target from August 20, 2026. Currently, 10 analysts provide opinions on the stock, resulting in a mean price target of $20.20. The estimates range from a low of $10.00 to a high of $30.00.

About Korro Bio

Korro Bio is a biopharmaceutical company that works on genetic medicines. It uses a specialized platform to edit RNA, aiming to treat rare diseases and more common conditions like Parkinson's and chronic pain. The company, which has a collaboration with Novo Nordisk A/S, focuses on developing treatments that differ from traditional DNA-based gene editing.

What to Watch at Korro Bio, Inc.

The recent insider selling by Formela Jean Francois and other executives occurred several months before the next earnings report in November. Investors often watch these planned sales to see if they align with the stock's price movements near technical support levels. While these filings show what happened in June, they do not necessarily represent the current sentiment of the insiders today.